Viking Therapeutics, Inc. (VKTX) stock
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.88+0.08 (+0.30%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Viking Therapeutics cash
Cash and short-term investments held at the end of each period.
Viking Therapeutics's cash was $959.81M at Sep 30, 2026. For fiscal 2025 it was $705.74M, down 21.8% from the year before. Over ten years it grew 97.8% a year on average. The highest annual figure on record is $902.61M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $705.74M | -21.8% |
| FY2024 | Dec 31, 2024 | $902.61M | +149.3% |
| FY2023 | Dec 31, 2023 | $362.08M | +132.9% |
| FY2022 | Dec 31, 2022 | $155.49M | -23.1% |
| FY2021 | Dec 31, 2021 | $202.10M | -18.6% |
| FY2020 | Dec 31, 2020 | $248.39M | -9.9% |
| FY2019 | Dec 31, 2019 | $275.64M | -8.6% |
| FY2018 | Dec 31, 2018 | $301.52M | +1365.5% |
| FY2017 | Dec 31, 2017 | $20.58M | +568.9% |
| FY2016 | Dec 31, 2016 | $3.08M | +300.2% |
| FY2015 | Dec 31, 2015 | $768.55K | +1.7% |
| FY2014 | Dec 31, 2014 | $755.86K | +320.8% |
| FY2013 | Dec 31, 2013 | $179.62K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $959.81M | +34.3% |
| Q2 FY2026 | Jun 30, 2026 | $501.66M | -37.9% |
| Q1 FY2026 | Mar 31, 2026 | $602.96M | -29.2% |
| Q4 FY2025 | Dec 31, 2025 | $705.74M | -21.8% |
| Q3 FY2025 | Sep 30, 2025 | $714.57M | -23.2% |
| Q2 FY2025 | Jun 30, 2025 | $807.72M | -14.3% |
| Q1 FY2025 | Mar 31, 2025 | $851.86M | -11.5% |
| Q4 FY2024 | Dec 31, 2024 | $902.61M | +149.3% |
| Q3 FY2024 | Sep 30, 2024 | $930.44M | +147.3% |
| Q2 FY2024 | Jun 30, 2024 | $942.26M | +139.8% |
| Q1 FY2024 | Mar 31, 2024 | $962.98M | +609.8% |
| Q4 FY2023 | Dec 31, 2023 | $362.08M | +132.9% |
| Q3 FY2023 | Sep 30, 2023 | $376.24M | +142.7% |
| Q2 FY2023 | Jun 30, 2023 | $392.92M | +132.6% |
| Q1 FY2023 | Mar 31, 2023 | $135.66M | -26.6% |
| Q4 FY2022 | Dec 31, 2022 | $155.49M | -23.1% |
| Q3 FY2022 | Sep 30, 2022 | $155.02M | -28.3% |
| Q2 FY2022 | Jun 30, 2022 | $168.92M | -26.0% |
| Q1 FY2022 | Mar 31, 2022 | $184.90M | -23.5% |
| Q4 FY2021 | Dec 31, 2021 | $202.10M | -18.6% |
| Q3 FY2021 | Sep 30, 2021 | $216.14M | -15.3% |
| Q2 FY2021 | Jun 30, 2021 | $228.26M | -13.2% |
| Q1 FY2021 | Mar 31, 2021 | $241.68M | -10.2% |
| Q4 FY2020 | Dec 31, 2020 | $248.39M | -9.9% |
| Q3 FY2020 | Sep 30, 2020 | $255.30M | -11.4% |
| Q2 FY2020 | Jun 30, 2020 | $263.00M | -10.1% |
| Q1 FY2020 | Mar 31, 2020 | $269.16M | -9.9% |
| Q4 FY2019 | Dec 31, 2019 | $275.64M | -8.6% |
| Q3 FY2019 | Sep 30, 2019 | $288.07M | -5.3% |
| Q2 FY2019 | Jun 30, 2019 | $292.64M | +745.5% |
| Q1 FY2019 | Mar 31, 2019 | $298.72M | +721.6% |
| Q4 FY2018 | Dec 31, 2018 | $301.52M | +1365.5% |
| Q3 FY2018 | Sep 30, 2018 | $304.16M | +11744.3% |
| Q2 FY2018 | Jun 30, 2018 | $34.61M | +919.7% |
| Q1 FY2018 | Mar 31, 2018 | $36.36M | +734.0% |
| Q4 FY2017 | Dec 31, 2017 | $20.58M | +568.9% |
| Q3 FY2017 | Sep 30, 2017 | $2.57M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.08M | – |
See a number that looks wrong?